ARS Pharmaceuticals, Inc.
neffy
Type I allergic reactions
Countdown
86days
Phase 2 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 2 trial results for neffy in Type I allergic reactions are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Phase 2b CSU interim population fully enrolled with topline results expected in Q4 2026 ($2B+ peak opportunity)”